Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
11 April 2018 Photo Leonie Bolleurs
First accredited ICS training in SA presented at UFS
Prof Andries Jordaan, Head of DiMTEC, with Greg Archer from the United States Forest Services, and Yong Sebastian Nyam, a DiMTEC PhD student from Cameroon.
The University of the Free State’s (UFS) Disaster Management Training and Education Centre for Africa (DiMTEC) and the Free State Umbrella Fire Protection Association (FSUFPA) presented the first training exercise in the Free State, offering practical experience regarding the implementation of the Incident Command System (ICS) under simulated emergency conditions.

An Exercise Coordination Team (ECT), consisting of US instructors, under the leadership of Mike Kopitzke from the United States Forest Services, together with Johann Breytenbach from FSUFPA and supported by local personnel, facilitated the exercise.

Training complete with sand table exercise 
This dual site desktop exercise took place at the Rooipoort Training Centre outside Dewetsdorp and the DiMTEC offices in the Agriculture Building on the UFS Bloemfontein Campus. The Incident Management Team (IMT) training – complete with a sand table exercise   was presented at Rooipoort, At the same time a simulation of an Emergency Operations Centre (EOC) was offered at the DiMTEC offices. 

According to Prof Andries Jordaan, Head of DiMTEC, the exercise was based on a variety of actual scenarios that had previously taken place elsewhere in the Free State. The exercise simulated a train and bus accident on the Thaba Nchu road. “Using an incident like this keeps the training realistic and relevant,” he said.

In these exercises the work of different departments, including South African Police Services (SAPS), South African National Defence Force (SANDF), Transnet, Spoornet, Traffic Department, and Eskom are coordinated. “We would like to work with the National Disaster Management Centre (NDMC) to implement a uniform Incident management system in South Africa where all departments speak the same language and have the same understanding of the role and responsibilities of a command structure,” Prof Jordaan said.

Accredited training the outcome
In 2017 Prof Jordaan, General Elias Mahlabane from the SAPS, and Johan Breytenbach from the FSUFPA, attended an incident command course in California in the US. They were introduced to the National Incident Management System (NIMS) in the US. The system was implemented after lessons learned during 9/11. “According to the NIMS structure, all government organisations at all levels, as well as emergency agencies, had to standardise terminology and systems,” said Prof Jordaan.

Insight gained during the visit and a work relationship with the United State Forest Services, provided Prof Jordaan and Breytenbach the necessary background to conduct training for incident management teams.

Currently DiMTEC is offering accredited ICS 100, 200 and 300 courses. To qualify as incident command managers, students need to attend the ICS courses together with the practical training. As part of the training they also need to shadow a qualified ICS manager during two real incidents. These courses are taking place in conjunction with the FSUFPA. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept